|Articles|October 8, 2021
- Pharmaceutical Executive-10-01-2021
- Volume 41
- Issue 10
Pharmaceutical Executive, October 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Addressing Systemic Racism in Biopharmaover 4 years ago
Understanding the HCP: Patient-Level Data Proves Valuableover 4 years ago
Industry Game Changer: RWE Impacts on Drug Developmentover 4 years ago
Opposites Attractover 4 years ago
Defining the Chief Data Officerover 4 years ago
Leading Through Transitionover 4 years ago
Biotech Stocks Continue With Underperformanceover 4 years ago
Could Time Be the Next New Element in Pharma Revenue?over 4 years ago
Sharing the Science: Pharma’s Content Evolutionover 4 years ago
Data Science Calls for Shift in Executive Leadership MethodsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Kinds of Disruption are GLP-1s Expected to Face
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Director of NIH Infectious Disease Institute Steps Down
4
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
5